Previous 10 | Next 10 |
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that its wholly owned subsidiary, Dr Reddy’s Laboratories, Inc, is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetam in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL (15 mg...
Dr. Reddy's Laboratories Limited (RDY) Q3 2019 Results Conference Call February 01, 2018 08:00 AM ET Company Participants Amit Agarwal - Director Finance and Investor Relations Erez Israeli - COO Saumen Chakraborty - CFO Anil Namboodiripad - Head of Proprietary Products Conf...
Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the appointment of Marc Kikuchi as Chief Executive Officer, North America Generics. As part of the Dr. Reddy...
Dr. Reddy's ( RDY ) Q3 results : Revenues: $553M (+1.1%). More news on: Dr. Reddy's Laboratories Limited, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter ended December 31, 2018 under International Financial Reporting Standards (IFRS). Commenting on the results, CEO and Co-chairman, G.V. Prasad ...
The following slide deck was published by Dr. Reddy's Laboratories Limited in conjunction with their 2019 Q3 earnings Read more ...
Dr. Reddy's (NYSE: RDY ): Q3 GAAP EPS of $0.42 beats by $0.16 . More news on: Dr. Reddy's Laboratories Limited, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Deal Overview On January 3, 2019, Bristol-Meyers Squibb ( BMY ) announced it would acquire Celgene ( CELG ) in a stock and cash transaction. BMY is offering $50 cash, 1 share of BMY valued at $52.43 the day before announcement, and a contingent value right (“CVR”) worth $9 ca...
The FDA approves Dr. Reddy’s Laboratories' (NYSE: RDY ) and its subsidiary, Promius Pharma's TOSYMRA 10 mg (previously known as DFN-02) for the acute treatment of migraine with or without aura in adults. More news on: Dr. Reddy's Laboratories Limited, Healthcare stocks news, R...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and its subsidiary, Promius Pharma, LLC today announced the approval of TOSYMRA (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). TOSYMRA is indicated for the acute treatment of migraine wi...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2024. The information mentioned in this release is based on consolidated financial statements under International Fina...
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...